TY - JOUR
T1 - Early triple negative breast cancer
T2 - Conventional treatment and emerging therapeutic landscapes
AU - Diana, Anna
AU - Carlino, Francesca
AU - Franzese, Elisena
AU - Oikonomidou, Olga
AU - Criscitiello, Carmen
AU - De Vita, Ferdinando
AU - Ciardiello, Fortunato
AU - Orditura, Michele
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4
Y1 - 2020/4
N2 - Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline-and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population.
AB - Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline-and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population.
KW - Biomarkers
KW - Immunotherapy
KW - Neo-(adjuvant)
KW - PARP inhibitors
KW - Triple negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85083007140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083007140&partnerID=8YFLogxK
U2 - 10.3390/cancers12040819
DO - 10.3390/cancers12040819
M3 - Review article
AN - SCOPUS:85083007140
VL - 12
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 4
M1 - 819
ER -